Iterum Holders’ Representative

Iterum Therapeutics is a pharmaceutical company focused on the development and commercialization of next-generation oral and intravenous antibiotics to treat multi-drug resistant pathogens. The company's lead product, ORLYNVA (sulopenem etzadroxil and probenecid), was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections (uUTI) in adult women with limited or no oral treatment options. Iterum aims to address the significant clinical need for potent, well-tolerated oral antibiotics that can be used in the community setting, potentially reducing the need for hospitalizations. The company's sulopenem program includes both oral and IV formulations for various serious infections, including complicated urinary tract infections and intra-abdominal infections. Iterum is headquartered in Dublin, Ireland, and maintains operations in the United States.